- Bill Farley has experience in pharmaceutical industry partnering, executive management, technology commercialization and company building
- Bill Farley has held leadership positions in multiple organizations
- XORTX also announces that it has granted 250,000 stock options to Mr. Farley
- XORTX Therapeutics Inc. is a biotechnology company working to create new therapeutics for kidney disease
- XORTX Therapeutics Inc. opened trading at C$0.165 per share
XORTX Therapeutics (XRX) is pleased to announce the appointment of Mr. William “Bill” Farley to the company’s Board of Directors.
Bill Farley has held leadership positions in multiple organizations, including Sorrento Therapeutics, Wuxi Apptec, Pfizer, and Johnson & Johnson.
Mr. Farley is a frequent speaker at industry conferences and has been published in a variety of journals.
“We are pleased to welcome and add an experienced life sciences industry professional of Bill’s caliber to the XORTX board of directors. Bill’s extensive pharmaceutical industry partnering, executive management, technology commercialization and company building experience will further enhance XORTX’s future growth opportunities,” stated Dr. Allen Davidoff, XORTX President and CEO.
Mr. Farley added,
“The opportunity to join the board of XORTX on the Company’s mission to create new therapeutics for kidney disease is an honor and privilege at this momentous time in the company’s growth trajectory.”
“Bill Farley will be a key person for XORTX as we move forward with global development plans,” commented Dr. David Sans, Corporate Development consultant supporting the President and CEO of XORTX, Dr. Allen Davidoff.
XORTX also announces that it has granted 500,000 options to purchase common shares, 250,000 to William Farley and 250,000 to a consultant. The options granted are exercisable at $0.16 for a period of five years.
XORTX Therapeutics Inc. is a biotechnology company with three clinically advanced products in development – XRx-008 for Autosomal Dominant Polycystic Kidney Disease (ADPKD), XRx-101 for Coronavirus / COVID-19 infection and XRx-225 is a pre-clinical stage program for Type 2 Diabetic Nephropathy (T2DN).
XORTX is working to advance its clinical development-stage products that target xanthine oxidase to inhibit the production of uric acid.
XORTX Therapeutics Inc. opened trading at C$0.165 per share.
